Predictors of Angiotensin-Converting Enzyme Inhibitor–Induced Reduction of Urinary Albumin Excretion in Nondiabetic Patients
- 1 November 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 48 (5) , 870-876
- https://doi.org/10.1161/01.hyp.0000244082.26293.2d
Abstract
Urinary albumin excretion is a predictor for cardiovascular mortality and morbidity. We investigated which parameters determine baseline urinary albumin excretion in nondiabetic subjects, without renal disease. In addition, we evaluated the parameters that predict the albuminuria-lowering efficacy of an angiotensin-converting enzyme inhibitor. In this substudy of the Prevention of Renal and Vascular Endstage Disease Intervention Trial, 384 microalbuminuric patients were included. Patient and biochemical characteristics were obtained at baseline and after 3 months of double-blinded, randomized treatment (fosinopril 20 mg or placebo). Mean age was 51.1±11.5 years, and 65.6% were male. Median urinary albumin excretion was 22.2 mg per 24 hours. At baseline, mean arterial pressure (βstandardized=0.161; P=0.006), urinary sodium excretion (βstandardized=0.154; P=0.011), and estimated renal function were independently associated with albumin excretion. In these predominantly normotensive to prehypertensive subjec...Keywords
This publication has 30 references indexed in Scilit:
- Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive PatientsHypertension, 2005
- Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General PopulationCirculation, 2002
- Albuminuria and Risk of Cardiovascular Events, Death, and Heart Failure in Diabetic and Nondiabetic IndividualsJAMA, 2001
- Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the prevention of REnal and vascular ENdstage disease intervention trial [PREVEND IT])The American Journal of Cardiology, 2000
- Long-Term Benefits of the Antiproteinuric Effect of Angiotensin-Converting Enzyme Inhibition in Nondiabetic Renal DiseaseAmerican Journal of Kidney Diseases, 1993
- Microalbuminuria in essential hypertension. Reduction by different antihypertensive drugs.Hypertension, 1993
- Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinoprilKidney International, 1989
- Albuminuria reflects widespread vascular damageDiabetologia, 1989
- Microalbuminuria Predicts Clinical Proteinuria and Early Mortality in Maturity-Onset DiabetesNew England Journal of Medicine, 1984
- MICROALBUMINURIA AS A PREDICTOR OF CLINICAL NEPHROPATHY IN INSULIN-DEPENDENT DIABETES MELLITUSThe Lancet, 1982